Sistema de Salut de Catalunya
Institut Català de la Salut
[Nag S] Medical Oncology Department, Sahyadri Superspeciality Hospital, Hadapsar, Pune, India. [Ray Coquard I] Medical Oncology Department, Centre Léon Bérard, Lyon, France. [Gupta S] Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, India. [Pathak A] Department of Medical Oncology, Cancer Care Clinic, Dhantoli, Nagpur, India. [Li N] Department of Gynecologic Oncology, National Cancer Centre, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [Mulya Sari R] Haematology-Medical Oncology Department, Dharmais National Cancer Center, Jakarta, Indonesia. [Oaknin A] Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-08-12T07:45:29Z
2025-08-12T07:45:29Z
2025-06
Pan-asian; Epithelial ovarian cancer; Treatment
Pan-asiàtic; Càncer epitelial d'ovari; Tractament
Pan-asiático; Cáncer epitelial de ovario; Tratamiento
The European Society for Medical Oncology (ESMO) Clinical Practice Guideline for the diagnosis, treatment and follow-up of patients with newly diagnosed and relapsed epithelial ovarian cancer (EOC), published in 2023, was adapted in July 2024, according to established standard methodology, to produce the Pan-Asian adapted ESMO consensus guideline for the management of Asian patients with EOC. The adapted guideline presented in this manuscript represents the consensus opinions reached by a panel of Asian experts in the treatment of patients with EOC representing the oncological societies of China, Indonesia, India, Japan, Korea, Malaysia, the Philippines, Singapore, Taiwan and Thailand, coordinated by ESMO and the Indian Society of Medical and Pediatric Oncology. Voting was based on scientific evidence and was independent of current treatment practices, drug access restrictions and reimbursement decisions in the represented countries. Drug access and reimbursement across Asia are discussed separately in the manuscript. The Pan-Asian consensus aims to guide the optimisation and harmonisation of management of patients with EOC in Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between countries.
All costs relating to this consensus conference were covered by ESMO from central dedicated funds. There was no external funding of the virtual event or the manuscript production.
Article
Published version
English
Ovaris - Càncer - Tractament; Ovaris - Càncer - Diagnòstic; Ovaris - Càncer - Recaiguda; Àsia; DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms::Carcinoma, Ovarian Epithelial; Other subheadings::Other subheadings::/diagnosis; HEALTH CARE::Health Services Administration::Patient Care Management::Disease Management; Asia; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local; ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas::carcinoma epitelial de ovario; Otros calificadores::Otros calificadores::/diagnóstico; ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::tratamiento de las enfermedades; DENOMINACIONES GEOGRÁFICAS::localizaciones geográficas::Asia; ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local
Elsevier
ESMO Open;10(6)
https://doi.org/10.1016/j.esmoop.2025.105125
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
